GlassScriptPhysician profile
David F Dougherty
NPI 1104261445
$145,456.68
in general payments reported to CMS, 2019-2025
23 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,941 · 2021: $15K · 2022: $17K · 2023: $31K · 2024: $28K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Travel and Lodging: $18K · Food and Beverage: $7,542 · Education: $22.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,063.00 |
| Travel and Lodging | $17,928.70 |
| Food and Beverage | $7,541.52 |
| Education | $22.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $139,611.05 | 2019-2025 | Biktarvy, Veklury, Yeztugo |
| Insmed, INC. | $1,120.61 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $936.24 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $681.22 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Shionogi INC | $651.08 | 2021-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $536.27 | 2022-2025 | Zevtera, Xacduro, Xerava |
| Astellas Pharma US INC | $413.52 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $379.54 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $255.41 | 2019-2025 | Nuzyra |
| Abbvie INC. | $132.75 | 2019-2025 | Dalvance |
| Aimmune Therapeutics, INC. | $123.48 | 2023-2025 | Vowst |
| Allergan, INC. | $112.91 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $109.91 | 2019-2025 | |
| Theratechnologies INC. | $82.31 | 2019-2025 | Egrifta Sv, Egrifta, Trogarzo |
| Janssen Biotech, INC. | $74.33 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $67.03 | 2024-2025 | Vibativ |
| Mayne Pharma Commercial LLC | $54.87 | 2019-2022 | |
| Pfizer INC. | $44.17 | 2023-2024 | |
| Pharming Healthcare, INC. | $21.45 | 2024 | Ruconest |
| Alexion Pharmaceuticals, INC. | $20.71 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.42 | 2024 | Rebyota |
| Vyera Pharmaceuticals, LLC | $13.40 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.